Specify Company / Ticker to Get the Summary
Iterum Therapeutics PLC
ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. Address: Fitzwilliam Court, Dublin, Ireland, D02 YW24
Analytics
WallStreet Target Price
7.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ITRM
Dividend Analytics ITRM
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ITRM
Stock Valuation ITRM
Financials ITRM
Results | 2019 | Dynamics |